Press Release / Health and Fitness / ABSSSI Market Insights, Epidemiology and Market Forecast-2028

ABSSSI Market Insights, Epidemiology and Market Forecast-2028

"DelveInsight’s ‘ABSSSI - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the ABSSSI market trends in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.
The Report provides the ABSSSI current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size from 2017 to 2028 segmented by seven major markets. The ABSSSI Report also covers ABSSSI current treatment practice/algorithm, ABSSSI market drivers, ABSSSI market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the ABSSSI market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
Study Period: 2017-2028

ABSSSI - Disease Understanding and Treatment Algorithm
According to the U.S. Food and Drug Administration (FDA), ABSSSI is defined as a bacterial infection of the skin with a lesion size area of ≥75 cm2 (lesion size measured by the area of redness, oedema or induration). ABSSSI consists of the most frequently diagnosed skin infections worldwide. The ABSSSI symptoms observed are extensive cellulitis, wound infection, major cutaneous abscesses, and burn infections. There are several pathogens that lead to ABSSSIs, such as Methicillin-sensitive Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and others.
The DelveInsight Acute Bacterial Skin and Skin-Structure Infection market report give the thorough understanding of the Acute Bacterial Skin and Skin-Structure Infection by including details such as disease definition, causes, symptoms, risk factors, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Bacterial Skin and Skin-Structure Infection in the US, Europe, and Japan.

ABSSSI Epidemiology
The ABSSSI epidemiology division provides insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight ABSSSI report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The ABSSSI epidemiology covered in the report provides historical as well as forecasted epidemiology (ABSSSI Total Incident Population, Gender-specific ABSSSI Incidence Cases, Subtype-specific Incidence Cases of Acute Bacterial Skin and Skin-Structure Infection, Incidence cases of ABSSSI by Clinical Manifestations, Diagnosed and Treatable Cases of scenario ofABSSSI in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
As per Kaye et al, a total of 1.8% of hospital admissions for the years 2005 through 2011 were for adult patients with a SSSI primary diagnosis. According to DelveInsight, the total number of ABSSSI incident population will change from the study period 2017-2028.

ABSSSI Drug Chapters
This segment of the ABSSSI report encloses the detailed analysis of ABSSSI marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
According to The Infectious Diseases, Society of America (IDSA) guidelines for the treatment of skin and soft tissue infections in 2014, the treatment of typical cases of cellulitis (ABSSSI major subtype) includes an oral antibiotic with activity against streptococci. Major treatment options for mild cases of non-purulent infections include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin. Oral and intravenous options for the ABSSSI treatment with activity against MRSA include several long-standing therapies, such as sulfamethoxazole-trimethoprim, clindamycin, minocycline, doxycycline, vancomycin, daptomycin, linezolid, ceftaroline, and telavancin. Antibiotics with activity against MRSA are considered when the infection is associated with penetrating trauma, such as IV drug use.
To meet the increasing demand for the ABSSSI treatment, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the ABSSSI market size in the coming years, assisted by an increase in the ABSSSI Incident population & awareness of the disease. The overall dynamics of ABSSSI market is anticipated to change in the coming years owing to the expected launch of ABSSSI emerging therapies of the major key players such as Merck Sharp & Dohme Corp., Motif Bio, MicuRx, Durata Therapeutics, Wockhardt and some others, will significantly increase the ABSSSI market during the forecast period (2019-2028).

ABSSSI Market Outlook
The ABSSSI market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the ABSSSI market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of ABSSSI market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the ABSSSI market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the ABSSSI market and view of the key opinion leaders. The calculated ABSSSI market data are presented with relevant tables and graphs to give a clear view of the ABSSSI market at first sight.
According to DelveInsight, the ABSSSI market in 7MM is expected to change from 2019-2028.

ABSSSI Drugs Uptake
This section focusses on the rate of uptake of the ABSSSI potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the ABSSSI drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of ABSSSI market share and ABSSSI market size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of ABSSSI therapies such as MK-1986 (Merck Sharp & Dohme Corp), Iclaprim (Motif Bio), MRX-I (MicuRx) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the ABSSSI market.

ABSSSI Report Insights

ABSSSI Patient Population
ABSSSI Therapeutic Approaches
ABSSSI Market Size and ABSSSI market Trends
ABSSSI Market Opportunities
Impact of ABSSSI upcoming Therapies
ABSSSI Report Key Strengths

10 Year Forecast
ABSSSI 7MM Coverage
ABSSSI Epidemiology Segmentation
ABSSSI Drugs Uptake
Highly Analyzed ABSSSI Market
Key Cross Competition
ABSSSI Report Assessment

ABSSSI Current Treatment Practices
ABSSSI Unmet Needs
ABSSSI Market Attractiveness
ABSSSI Market Drivers and Barriers
Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving ABSSSI market
Organize sales and marketing efforts by identifying the best opportunities for ABSSSI market